Legal & General Group
CCCC icon

Legal & General Group’s C4 Therapeutics CCCC Stock Holding History

Legal & General Group’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-5,063
Closed -$8.07K – 3438
2025
Q1 		$8.07K Hold
5,063
– – ﹤0.01% 3215
2024
Q4 		$18.2K Hold
5,063
– – ﹤0.01% 3053
2024
Q3 		$28.9K Hold
5,063
– – ﹤0.01% 2910
2024
Q2 		$23.3K Buy
+5,063
New +$30.2K ﹤0.01% 2960
2023
Q2 		– Sell
-5,591
Closed -$17.6K – 3429
2023
Q1 		$17.6K Sell
5,591
-7,844
-58% -$46.2K ﹤0.01% 3101
2022
Q4 		$79.3K Buy
13,435
+1,072
+9% +$8.89K ﹤0.01% 2866
2022
Q3 		$109K Buy
12,363
+1,017
+9% +$10.6K ﹤0.01% 2793
2022
Q2 		$86K Buy
11,346
+3,755
+49% +$33K ﹤0.01% 2894
2022
Q1 		$185K Sell
7,591
-24
-0.3% -$583 ﹤0.01% 2699
2021
Q4 		$245K Buy
7,615
+524
+7% +$20.7K ﹤0.01% 2630
2021
Q3 		$317K Buy
7,091
+2,520
+55% +$108K ﹤0.01% 2549
2021
Q2 		$173K Buy
4,571
+3,477
+318% +$125K ﹤0.01% 2576
2021
Q1 		$40K Sell
1,094
-44
-4% -$1.75K ﹤0.01% 2889
2020
Q4 		$38K Buy
+1,138
New +$33K ﹤0.01% 2874

Other funds holding CCCC

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Legal & General Group's CCCC Position: Q2 2025 in Review

Legal & General Group sold out of C4 Therapeutics (CCCC) in Q2 2025, closing a stake of 5,063 shares — an estimated $8.07K sold.

Legal & General Group first reported a position in CCCC in Q4 2020 and held it in 14 quarters. The position peaked at $317K in Q3 2021. 102 funds tracked by Wall St. Rank hold CCCC as of Q2 2025.

  • Legal & General Group reported no remaining C4 Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Legal & General Group sold 5,063 C4 Therapeutics shares in Q2 2025, an estimated $8.07K.
  • Legal & General Group first reported a position in C4 Therapeutics in Q4 2020 and held it in 14 quarters.
  • Legal & General Group's C4 Therapeutics position peaked at $317K in Q3 2021.
  • 102 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2025.

Based on Legal & General Group's 13F filing for Q2 2025, filed 12 Aug 2025.